Australia delivers

Landet down under passar på att införskaffa sig 2 nya HoloMonitor.Det handlar alltså om ett av Australiens bästa universitet, Queensland University of Technology (QUT).Den minnesgode kommer ihåg de 2 QUT-forskarna Derek Richard och Ken O'Byrne som 2018 skapade rejält med uppmärksamhet  världen över med  sitt utrop “We believe we’ve found the Holy Grail”. Med HoloMonitors assistans visade forskarna att det gick att reparera skadad DNA i människa.

- Associate Professor Derek Richard, at Queensland University of Technology in Australia, has, with help from HoloMonitor M4, found a way to turn back time and make old cells young again.

QUT researchers have developed a new drug that has the potential to dramatically slow the ageing process and delay, or even prevent, major diseases in humans, including cancer, Alzheimer’s, Type 2 Diabetes and arthritis.

The Scientific Director of the Cancer and Ageing Research Program (CARP), Associate Professor Derek Richard from QUT’s Institute of Health and Biomedical Innovation, said the breakthrough was built upon years of research focused on the ability of single-cell organisms called archaea to survive in harsh conditions, including the boiling, sulphuric acid pools of undersea volcanoes.

“Our research into arachaei revealed a ‘super hero’ protein, known as ssB1. But the real eureka moment came when we discovered that humans have this same protein, called hSSB1, in every cell of our bodies,” Professor Richard said.
“In normal cells, ssB1 is like a guardian angel that is looking after the genetic code and, if there is any damage, we see it rush in to repair that damage. But, as we age, we lose parts of our genetic code, and that is the foundation for diseases such as cancer and Alzheimer’s.
“When we found that ssB1 was helping the archaea to repair its damaged DNA, we realised we might have stumbled across the basis for a new cellular treatment for humans, to control our ageing pathway and keep people healthier, for longer.
“This new drug functions by restoring the activity of the DNA-repairing, ‘super hero’ hSSB1 protein in our bodies and we can make cells believe that they are much younger than they actually are,” Professor Richard said.

QUT Professor and CARP clinical director, oncologist Ken O’Byrne, said while the drug had the potential to prevent or delay the onset of disease and illness, the primary aim was to improve quality of life.
“The big link between cancer and ageing is DNA repair. As we age, our target protein starts to function differently and allows our genome to be damaged and this damage can cause cancer,” Professor O’Byrne said.
“This drug, once fully developed, could actually be taken to protect high-risk individuals from cancer and other diseases,” he said.

Samma Universitet har alltså utökat med 2 HoloMonitor till berättar PHI på hemsidan.

HoloMonitor down-under – Freya & Olaf advance QUT research

October 26, 2020 | Blog | Brisbane

Freya and Olaf – two HoloMonitor systems – are expanding Queensland University of Technology’s Live Cell Imaging capabilities.

Restrictions and lockdowns have posed many challenges on the world. Researchers at Queensland University of Technology (QUT) have been longing to run experiments with HoloMonitor® since their delivery seven months ago, and now the wait is finally over! Recently, the two systems were installed and are ready to run!

QUT houses the Cell Analysis Facility (CAF) – and they are proud to provide real-world infrastructure to their staff and students. CAF has a suite of high-end imaging systems, and now, they have two HoloMonitors to expand their capabilities in Live Cell Imaging & Analysis.

The two HoloMonitor systems enable researchers to investigate their cells for drug development in the fields of cancer, infection, and regenerative medicine – using both single-cell analysis and cell population assays.

Thank you to Jamie Mulders from our Australian HoloMonitor distributor TrendBio Pty Ltd for sharing the news!

QUT är ett ambitiöst universitet med forskning kring ett flertal cancertyper.

"Our cancer research area combines the activities of multidisciplinary research teams with the aim of improving outcomes for cancer patients.

We operate a strong collaborative research model where molecular and cellular biologists work alongside bioinformaticians, medicinal chemists, surgeons, oncologists and industrial partners to provide a real bench-to-bedside approach to tackling this disease."

Research programs

• Prostate cancer
• Breast cancer
• Ovarian cancer
• Endometrial cancer
• Lung cancer
• Melanoma

Som en tribute till QUT lägger jag in denna fräsiga och välljudande presentation.